These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24456799)

  • 1. Transplantation of umbilical cord-derived mesenchymal stem cells into the striata of R6/2 mice: behavioral and neuropathological analysis.
    Fink KD; Rossignol J; Crane AT; Davis KK; Bombard MC; Bavar AM; Clerc S; Lowrance SA; Song C; Lescaudron L; Dunbar GL
    Stem Cell Res Ther; 2013 Oct; 4(5):130. PubMed ID: 24456799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reductions in behavioral deficits and neuropathology in the R6/2 mouse model of Huntington's disease following transplantation of bone-marrow-derived mesenchymal stem cells is dependent on passage number.
    Rossignol J; Fink KD; Crane AT; Davis KK; Bombard MC; Clerc S; Bavar AM; Lowrance SA; Song C; Witte S; Lescaudron L; Dunbar GL
    Stem Cell Res Ther; 2015 Feb; 6(1):9. PubMed ID: 25971780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal Administration of Mesenchymal Stem Cells Ameliorates the Abnormal Dopamine Transmission System and Inflammatory Reaction in the R6/2 Mouse Model of Huntington Disease.
    Yu-Taeger L; Stricker-Shaver J; Arnold K; Bambynek-Dziuk P; Novati A; Singer E; Lourhmati A; Fabian C; Magg J; Riess O; Schwab M; Stolzing A; Danielyan L; Nguyen HHP
    Cells; 2019 Jun; 8(6):. PubMed ID: 31208073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease.
    Dey ND; Bombard MC; Roland BP; Davidson S; Lu M; Rossignol J; Sandstrom MI; Skeel RL; Lescaudron L; Dunbar GL
    Behav Brain Res; 2010 Dec; 214(2):193-200. PubMed ID: 20493905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease.
    Linares GR; Chiu CT; Scheuing L; Leng Y; Liao HM; Maric D; Chuang DM
    Exp Neurol; 2016 Jul; 281():81-92. PubMed ID: 27085395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models.
    Lin YT; Chern Y; Shen CK; Wen HL; Chang YC; Li H; Cheng TH; Hsieh-Li HM
    PLoS One; 2011; 6(8):e22924. PubMed ID: 21850243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection of Transplanting Human Umbilical Cord Mesenchymal Stem Cells in a Microbead Induced Ocular Hypertension Rat Model.
    Ji S; Lin S; Chen J; Huang X; Wei CC; Li Z; Tang S
    Curr Eye Res; 2018 Jun; 43(6):810-820. PubMed ID: 29505314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transplants of adult mesenchymal and neural stem cells provide neuroprotection and behavioral sparing in a transgenic rat model of Huntington's disease.
    Rossignol J; Fink K; Davis K; Clerc S; Crane A; Matchynski J; Lowrance S; Bombard M; Dekorver N; Lescaudron L; Dunbar GL
    Stem Cells; 2014 Feb; 32(2):500-9. PubMed ID: 23939879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes.
    Rossignol J; Boyer C; Lévèque X; Fink KD; Thinard R; Blanchard F; Dunbar GL; Lescaudron L
    Behav Brain Res; 2011 Mar; 217(2):369-78. PubMed ID: 21070819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The absence of the aryl hydrocarbon receptor in the R6/1 transgenic mouse model of Huntington's disease improves the neurological phenotype.
    Angeles-López QD; García-Lara L; Aguirre-Pineda N; Castañeda-Arellano R; Elizondo-Azuela G; Pérez-Severiano F; Segovia J
    Behav Brain Res; 2021 Jun; 408():113230. PubMed ID: 33684424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
    Seo H; Kim W; Isacson O
    Hum Mol Genet; 2008 Oct; 17(20):3144-53. PubMed ID: 18640989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
    Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W
    Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Umbilical cord mesenchymal stem cells: adjuvants for human cell transplantation.
    Friedman R; Betancur M; Boissel L; Tuncer H; Cetrulo C; Klingemann H
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1477-86. PubMed ID: 18022578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Promising Effects of Transplanted Umbilical Cord Mesenchymal Stem Cells on the Treatment in Traumatic Brain Injury.
    Qi L; Xue X; Sun J; Wu Q; Wang H; Guo Y; Sun B
    J Craniofac Surg; 2018 Oct; 29(7):1689-1692. PubMed ID: 30234712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
    Dufour BD; McBride JL
    Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease.
    Rattray I; Smith EJ; Crum WR; Walker TA; Gale R; Bates GP; Modo M
    PLoS One; 2013; 8(12):e84726. PubMed ID: 24367693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.
    Stack EC; Kubilus JK; Smith K; Cormier K; Del Signore SJ; Guelin E; Ryu H; Hersch SM; Ferrante RJ
    J Comp Neurol; 2005 Oct; 490(4):354-70. PubMed ID: 16127709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditioned medium from amniotic cells protects striatal degeneration and ameliorates motor deficits in the R6/2 mouse model of Huntington's disease.
    Giampà C; Alvino A; Magatti M; Silini AR; Cardinale A; Paldino E; Fusco FR; Parolini O
    J Cell Mol Med; 2019 Feb; 23(2):1581-1592. PubMed ID: 30585395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes.
    Popovic N; Maingay M; Kirik D; Brundin P
    Exp Neurol; 2005 May; 193(1):65-74. PubMed ID: 15817265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.